DOCSLIB.ORG

DRUG MARKET TRENDS: CANNABIS OPIOIDS © United Nations, June 2021

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
DRUG MARKET TRENDS: CANNABIS OPIOIDS © United Nations, June 2021 DRUG MARKET TRENDS: CANNABIS OPIOIDS © United Nations, June 2021. All rights reserved worldwide. ISBN: 9789211483611 WORLD DRUG REPORT 2021 REPORT DRUG WORLD eISBN: 9789210058032 United Nations publication, Sales No. E.21.XI.8 This publication may be reproduced in whole or in part and in any form for educational or non-profit purposes without special permission from the copyright holder, provided acknowledgement of the source is made. The United Nations Office on Drugs and Crime (UNODC) would appreciate receiving a copy of any publication that uses this publication as a source. Suggested citation: World Drug Report 2021 (United Nations publication, Sales No. E.21.XI.8). No use of this publication may be made for resale or any other commercial purpose whatsoever without prior permission in writing from UNODC. Applications for such permission, with a statement of purpose and intent of the reproduction, should be addressed to the Research and Trend Analysis Branch of UNODC. DISCLAIMER The content of this publication does not necessarily reflect the views or policies of UNODC or contributory organizations, nor does it imply any endorsement. Comments on the report are welcome and can be sent to: Division for Policy Analysis and Public Affairs United Nations Office on Drugs and Crime PO Box 500 1400 Vienna Austria Tel: (+43) 1 26060 0 Fax: (+43) 1 26060 5827 E-mail: [email protected] 2 Website: www.unodc.org/unodc/en/data-and-analysis/wdr2021.html PREFACE 3 Drugs cost lives. unemployment and inequalities, as the world lost 114 million jobs in 2020. In doing, so it has created conditions that leave In an age when the speed of information can often outstrip more people susceptible to drug use and to engaging in illicit Preface the speed of verification, the COVID-19 pandemic has taught crop cultivation. us that it is crucial to cut through the noise and focus on facts, a lesson that we must heed in order to protect societies from Furthermore, disparities in access to essential controlled med- the impact of drugs. icines around the world continue to deny relief to patients in severe pain. In 2019, four standard doses of controlled pain Drug use killed almost half a million people in 2019, while drug medication were available every day for every one million inhab- use disorders resulted in 18 million years of healthy life lost, itants in West and Central Africa, in comparison to 32,000 mostly due to opioids. Serious and often lethal illnesses are doses in North America. more common among drug users, particularly those who inject drugs, many of whom are living with HIV and Hepatitis C. In parallel, drug traffickers have quickly recovered from the OPIOIDS | CANNABIS, initial setback caused by lockdown restrictions and are oper- The illicit drug trade also continues to hold back economic and ating at pre-pandemic levels once again. Access to drugs has social development, while disproportionately impacting the also become simpler than ever with online sales, and major most vulnerable and marginalized, and it constitutes a fun- drug markets on the dark web are now worth some $315 mil- damental threat to security and stability in some parts of the lion annually. Contactless drug transactions, such as through world. the mail, are also on the rise, a trend possibly accelerated by Despite the proven dangers, drug use persists and, in some the pandemic. contexts, proliferates. Over the past year, around 275 million Communicating facts about drugs and promoting science-based people have used drugs, up by 22 per cent from 2010. By 2030, interventions is an absolute necessity if we are to reduce demographic factors project the number of people using drugs demand and supply of drugs, while also facilitating access to to rise by 11 per cent around the world, and as much as 40 per controlled medicines for those in need. It is also the surest path cent in Africa alone. to eliminating stigmatization and discrimination and providing There is often a substantial disconnect between real risks and adequate treatment, as seven in eight people who suffer from public perception. In some parts of the world for example, can- drug use disorders remain without appropriate care. nabis products have almost quadrupled in potency, and yet the At the UN Office on Drugs and Crime we are dedicated to pursu- percentage of adolescents who perceive cannabis as harmful ing and promoting fact-driven, human rights-based approaches has dropped by as much as 40 per cent, despite the evidence to drug control and treatment. linking regular use to health problems, particularly in young people, and despite the correlation between potency and harm. I am proud to present to you this World Drug Report, which embodies our commitment to raising awareness and combat- New psychoactive substances also continue to be a challenge, as ing misinformation. markets witness the introduction of new drugs that are unpre- dictable and poorly understood. Regulatory and legislative It is my hope that this report will inform policymakers, practi- steps have been successful in stemming the tide globally, but tioners, and the general public on the facts of the world drug in low-income countries the problem is on the rise; between problem, and provide them with a powerful tool to share evi- 2015 and 2019, South and Central America recorded a fivefold dence and information, and in doing so help save and preserve rise in the amount of new synthetic psychoactive substances lives. seized, while seizures in Africa increased from minor to sub- stantial amounts. Strong increases were also reported in South and Southwest Asia as well as the Near and Middle East. Meanwhile, the COVID-19 crisis has pushed more than 100 Ghada Waly, Executive Director million people into extreme poverty, and has greatly exacerbated United Nations Office on Drugs and Crime 3 WORLD DRUG REPORT 2021 EXECUTIVE SUMMARY POLICY IMPLICATIONS BOOKLET GLOBAL OVERVIEW OF DRUG DEMAND AND DRUG SUPPLY BOOKLET DRUG MARKET TRENDS: CANNABIS, OPIOIDS BOOKLET DRUG MARKET TRENDS: COCAINE, AMPHETAMINE-TYPE STIMULANTS BOOKLET COVID-19 AND DRUGS: IMPACT AND OUTLOOK BOOKLET CONTENTS 3 PREFACE 3 EXPLANATORY NOTES 7 Contents SCOPE OF THE BOOKLET 9 CANNABIS 11 Cannabis supply 11 Cannabis use 19 Developments in measures regulating the non-medical use of cannabis 31 CANNABIS, OPIOIDS | OPIOIDS | CANNABIS, OPIOIDS 57 Overlap between the use of opioids 57 Demand for opioids 65 Access to pharmaceutical opioids for pain management 79 Supply of opiates 85 Supply of other opioids 97 ANNEX 105 GLOSSARY 121 REGIONAL GROUPINGS 123 5 Acknowledgements The World Drug Report 2021 was prepared by the Research and Trend Analysis Branch, Division for Policy Analysis and Public Affairs, United Nations Office on Drugs and Crime (UNODC), under the supervision of Jean-Luc Lemahieu, Director of the Division, and Angela Me, Chief of the Research and Trend Analysis Branch, and the coordination of Chloé Carpentier, Chief of the Drug Research Section. Content overview Mapping Chloé Carpentier Antero Keskinen Angela Me Francesca Massanello Irina Tsoy WORLD DRUG REPORT 2021 REPORT DRUG WORLD Analysis and drafting Kamran Niaz Editing Thomas Pietschmann Jonathan Gibbons Data management and estimate Graphic design and production production Anja Korenblik Enrico Bisogno Suzanne Kunnen Diana Camerini Kristina Kuttnig Hernan Epstein Maria Moser Natalia Ivanova Lorenz Perszyk Andrea Oterová Umidjon Rakhmonberdiev Data support Francesca Rosa Natalia Ivanova Ali Saadeddin Administrative support Andrada-Maria Filip Iulia Lazar Review and comments The World Drug Report 2021 benefited from the expertise of and invaluable contributions from UNODC colleagues in all divisions and from the INCB Secretariat. The Research and Trend Analysis Branch acknowledges the invaluable contributions and advice provided by the World Drug Report Scientific Advisory Committee: Jonathan Caulkins Afarin Rahimi-Movaghar Paul Griffiths Peter Reuter Marya Hynes Alison Ritter Vicknasingam B. Kasinather Francisco Thoumi Charles Parry The analysis on access to pharmaceutical opioids in Booklet 3 is based on original data graciously shared by the 6 INCB Secretariat. EXPLANATORY NOTES 3 The designations employed and the presentation of The following abbreviations have been used in the the material in the World Drug Report do not imply the present booklet: expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal alpha-PVP alpha-pyrrolidinovalerophenone status of any country, territory, city or area, or of its CBD cannabidiol authorities, or concerning the delimitation of its frontiers or boundaries. COVID-19 coronavirus disease notes Explanatory Countries and areas are referred to by the names that DALYs disability-adjusted life years were in official use at the time the relevant data were Δ-9-THC delta-9-tetrahydrocannabinol collected. ECOWAS Economic Community of West African States Since there is some scientific and legal ambiguity about the distinctions between “drug use”, “drug misuse” and EMCDDA European Monitoring Centre for Drugs and “drug abuse”, the neutral term “drug use” is used in the Drug Addiction World Drug Report. The term “misuse” is used only to Europol European Union Agency for OPIOIDS | CANNABIS, denote the non-medical use of prescription drugs. Law Enforcement Cooperation All uses of the word “drug” and the term “drug use” in ha hectares the World Drug Report refer to substances controlled INCB International Narcotics Control Board under the international drug control conventions, and their non-medical use. NPS new psychoactive substances All analysis contained in the World Drug Report is based S-DDD defined daily doses for statistical purposes on the official data submitted by Member States to the UNODC United Nations Office on Drugs and Crime UNODC through the annual report questionnaire unless indicated otherwise. WHO World Health Organization The data on population used in the World Drug Report are taken from: World Population Prospects: The 2019 Revision (United Nations, Department of Economic and Social Affairs, Population Division).
Load more

Recommended publications
  • Pioneering the Future of Global Cannabis June 2020
    Pioneering the Future of Global Cannabis June 2020 ©2020 TILRAY Disclaimer Investors and prospective investors should rely only on the information contained in the continuous expected; that adverse changes or developments affecting the Company’s main or planned facilities may Although management has attempted to identify important risk factors that could cause actual results to disclosure filings (the “Filings”) of Tilray Inc. (the “Company”). This presentation is qualified in its entirety have an adverse effect on the Company; that the medical cannabis industry and market may not continue differ materially from those contained in the forward-looking information in this presentation, there may by reference to, and must be read in conjunction with, the information contained in the Filings. An investor to exist or develop as anticipated or the Company may not be able to succeed in this market; that the be other risk factors not presently known to the Company or that the Company presently believes are not or prospective investor is not entitled to rely on parts of the information contained in this presentation to Company has a limited operating history and a history of net losses and that it may not achieve or maintain material that could also cause actual results or future events to differ materially from those expressed in the exclusion of others, and the Company is not authorized to provide different or additional information. profitability in the future; risks related to the Company’s current or proposed international operations; risks such forward-looking information in this presentation. There can be no assurance that such information Unless otherwise specified, all monetary amounts in this presentation are in United States dollars.
    [Show full text]
  • Clearing the Smoke on Cannabis: Regular Use and Cognitive Functioning
    6 Clearing the Smoke on Cannabis Regular Use and Cognitive Functioning Robert Gabrys, Ph.D., Research and Policy Analyst, CCSA Amy Porath, Ph.D., Director, Research, CCSA Key Points • Regular use refers to weekly or more frequent cannabis use over a period of months to years. Regular cannabis use is associated with mild cognitive difficulties, which are typically not apparent following about one month of abstinence. Heavy (daily) and long-term cannabis use is related to more This is the first in a series of reports noticeable cognitive impairment. that reviews the effects of cannabis • Cannabis use beginning prior to the age of 16 or 17 is one of the strongest use on various aspects of human predictors of cognitive impairment. However, it is unclear which comes functioning and development. This first — whether cognitive impairment leads to early onset cannabis use or report on the effects of chronic whether beginning cannabis use early in life causes a progressive decline in cannabis use on cognitive functioning cognitive abilities. provides an update of a previous report • Regular cannabis use is associated with altered brain structure and function. with new research findings that validate Once again, it is currently unclear whether chronic cannabis exposure and extend our current understanding directly leads to brain changes or whether differences in brain structure of this issue. Other reports in this precede the onset of chronic cannabis use. series address the link between chronic • Individuals with reduced executive function and maladaptive (risky and cannabis use and mental health, the impulsive) decision making are more likely to develop problematic cannabis use and cannabis use disorder.
    [Show full text]
  • Medical Cannabis Q&A
    Medical Cannabis Q&A 1. What is medical cannabis? The term “medical cannabis” is used to describe products derived from the whole cannabis plant or its extracts containing a variety of active cannabinoids and terpenes, which patients take for medical reasons, after interacting with and obtaining authorization from their health care practitioner. 2. What are the main active ingredients? The chemical ingredients of cannabis are called cannabinoids. The two main therapeutic ones are: THC:CBD a. Tetrahydrocannabinol (THC) is a partial agonist of CB1 and CB2 receptors. It is psychoactive and produces the euphoric effect. Each cannabis product will contain THC and CBD, however b. Cannabidiol (CBD) has a weak affinity for CB1 and CB2 receptors and appears the THC: CBD ratio will differ to exert its activity by enhancing the positive effects of the body’s endogenous depending on the product. cannabinoids. 3. Why do patients take it? Medical cannabis may be used to alleviate symptoms for a variety of conditions. It has most commonly been used in neuropathic pain and other chronic pain conditions. There is limited, but developing clinical evidence surrounding its safety and efficacy, and it does not currently have an approved Health Canada indication. 4. How do patients take it? Cannabis can be smoked, vaporized, taken orally, sublingually, topically or rectally. Different routes of administration will result in different pharmacokinetic and pharmacodynamic properties of the drug. 5. Is it possible to develop dependence on medical cannabis? Yes, abrupt discontinuation after long-term use may result in withdrawal symptoms. Additionally, chronic use may result in psychological dependence.
    [Show full text]
  • In Focus Cannabis Legalization 4
    IN FOCUS CANNABIS LEGALIZATION 4 2020 Developments in jurisdictions with measures regulating the non-medical use of cannabis of cannabis products for medical purposes had DEVELOPMENTS IN already been allowed in Canada as early as 1999. JURISDICTIONS WITH The objectives of the current cannabis legislation in MEASURES REGULATING Canada are to keep cannabis away from young people (under 18 years of age), to prevent criminals THE NON-MEDICAL USE from profiting from the distribution and sale of can- OF CANNABIS nabis and to safeguard public health and safety by allowing adults (aged 18 and older) legal access to As at December 2019, legal provisions had been cannabis.322 Under the constitutional division of approved in Canada, Uruguay and in 11 jurisdic- powers in Canada, the federal Government and pro- tions in the United States, including the District of vincial governments have different responsibilities.323 Columbia and the Northern Mariana Islands, to As the provinces historically developed their own allow the production and sale of cannabis products systems to regulate the sale of alcohol, a similar for non-medical use. The common feature of the approach has been applied to regulate the non-med- legislation in Canada and in the jurisdictions in the ical use of cannabis products. United States is that most of them allow for-profit To monitor the outcome of the new cannabis reg- industry to produce and sell cannabis products for ulations, the Government of Canada has invested non-medical use. There are some differences in the in a formal system that may eventually help to eval- level of regulation, its implementation and the con- uate their impact and support the further trol of the non-medical use of cannabis (see tables development of policies and programmes.
    [Show full text]
  • Medical Cannabis Cultivation Center Application Illinois Department of Agriculture Springfield, Illinois
    Medical Cannabis Cultivation Center Application Illinois Department of Agriculture Springfield, Illinois Schedule 1 – Suitability of the Proposed Facility The following Measures are found in Section 1000.110(b)(1) of the rules: Measure 1: The applicant must demonstrate that the proposed facility is suitable for effective and safe cultivation of medical cannabis, is sufficient in size, power allocation, air exchange and air flow, interior layout, lighting, and sufficient both in the interior and exterior to handle the bulk agricultural production of medical cannabis, cannabis-infused products, product handling, storage, trimming, packaging, loading and shipping. The loading/unloading of medical cannabis in the transport motor vehicle for shipping shall be in an enclosed, secure area out of public sight. Measure 2: The applicant must demonstrate the ability to continue to meet qualifying patient demand by expanding the cultivation facility in a quick and efficient manner with minimal impact on the environment and the surrounding community. Measure 3: The applicant provides an employee handbook that will provide employees with a working guide to the understanding of the day-to-day administration of personnel policies and practices. The following outline is meant as a guide for the applicant to follow in submitting information to meet the above Measures. It is not an all-inclusive list or description of required information. It is the applicant's responsibility to demonstrate compliance with the rules and application instructions. Any engineering drawings, flow diagrams, and descriptions must be adequate to illustrate your plans. 1. Location Area Map (1000.40(e), 1000.100(d)(19), 1000.220(a)) Provide a location map of the area surrounding the facility.
    [Show full text]
  • DEPARTMENT of JUSTICE Drug Enforcement
    This document is scheduled to be published in the Federal Register on 08/03/2021 and available online at DEPARTMENT OF JUSTICEfederalregister.gov/d/2021-16499, and on govinfo.gov Drug Enforcement Administration Bulk Manufacturer of Controlled Substances Application: Cerilliant Corporation [Docket No. DEA-873] AGENCY: Drug Enforcement Administration, Justice. ACTION: Notice of application. SUMMARY: Cerilliant Corporation has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplemental Information listed below for further drug information. DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before [INSERT DATE 60 DAYS AFTER DATE OF PUBLICATION IN THE FEDERAL REGISTER]. Such persons may also file a written request for a hearing on the application on or before [INSERT DATE 60 DAYS AFTER DATE OF PUBLICATION IN THE FEDERAL REGISTER]. ADDRESS: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this is notice that on June, 24, 2021, Cerilliant Corporation, 811 Paloma Drive, Suite A, Round Rock, Texas 78665-2402, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s): Controlled Substance Drug Code Schedule 3-Fluoro-N-methylcathinone
    [Show full text]
  • Williamstown Cannabis Cultivation Business Plan
    Williamstown Cannabis Cultivation Business Plan Davis Collison and Rosa Kirk-Davidoff We are on the stolen land of the Stockbridge-Munsee Band of the Mohican. “The legal marijuana industry has the potential to save local farms and repair a broken food system.”- Suehiko Ono, EOS Farms Introduction Averill Cook Davis and Rosa ● Who we are ● Environmental Planning ○ Senior Seminar for Environmental Studies Majors ● This project - Williamstown Cannabis Cultivation ● Questions: Best scale to start? Opportunities for a craft market? Jake Zieminski Our Clients ● Averill H Cook ○ Born and raised in Williamstown. ○ BS degree from University of Vermont ○ Owned and operated a pellet manufacturing business for 12 years ○ Traveled throughout numerous countries consulting in wood energy ○ Maintained an operated Wendling Farm in Williamstown where he grew up ○ Superior land stewardship has been paramount throughout his career Averill Cook Jake Zieminski Our Clients ● Jake Zieminski ○ Born and raised in Cheshire Ma on family dairy farm. Lived in Boston for 20 years and recently moved family back in 2018 to launch cannabis start-up. ○ Cannabis Entrepreneur ■ Current owner of CAVU Hemp, Cheshire Ma- MDAR licensed 2019 ■ 2021- CCC – Marijuana Cultivation Applicant ■ Cannabis Activist, Educator and Advisor since 2014 ○ Prior to transitioning into Cannabis industry in 2018, Mr. Zieminski was a management consultant focused in healthcare. Mr. Zieminski has spent the primary part of his career in client based performance improvement roles at PricewaterhouseCoopers(PwC),
    [Show full text]
  • Legalisation in South America
    Interest in medical cannabis is growing worldwide, resulting in many countries legalising cannabis for medical use. In particular, the South American market is progressing rapidly and has become a focus for biotech companies seeking to gain a foothold in the global medicinal cannabis market. Consumer perceptions are shifting, with recent studies showing 70% of South Americans agree with the use of medical cannabis and 51% are in favour of legalising cannabis9. However, legislation is still catching up as only six countries in South America have legalised cannabis for medical or recreational use – these are: Argentina, Brazil, Chile, Colombia, Paraguay and Uruguay1. LEGALISATION IN SOUTH AMERICA Argentina – as of March 2017, Argentina has legalised cannabis oil for the treatment of serious medical conditions2. This new law permits the cultivation of cannabis for distribution and research2. The Argentinean government also provides a medical cannabis research program that guarantees free access to cannabis oil to patients who join the program12. Brazil - has the largest population of any country in South America and has partially legalised cannabis use11. To date, the government has decriminalised the possession of small amounts of cannabis1. However, support for cannabis use is growing as in March 2017, the health department of Brazil approved the country’s first-ever license to sell a cannabis-based medical product, Mevatyl (also known as Sativex)3 which is a mouth spray for multiple sclerosis patients2. Colombia - has legalised cannabis for medical use1. This move was made in the hope of diminishing Colombia’s drug trafficking business13. As part of its peace process with the Revolutionary Armed Forces of Colombia (FARC), Colombia also plans to offer a crop substitution program for farmers of illegal coca crops to cultivate cannabis legally instead1.
    [Show full text]
  • When It Comes to Cannabis Potency?
    Testimony Should Canada “Start Low and Go Slow” When It Comes to Cannabis Potency? CT-­492 Testimony presented before the Standing Committee on Social Affairs, Science, and Technology Senate of Canada on May 7, 2018. C O R P O R A T I O N For more information on this publication, visit www.rand.org/pubs/testimonies/CT492.html Testimonies RAND testimonies record testimony presented or submitted by RAND associates to federal, state, or local legislative committees; government-appointed commissions and panels; and private review and oversight bodies. Published by the RAND Corporation, Santa Monica, Calif. © Copyright 2018 RAND Corporation RA® is a registered trademark. Limited Print andElectronic Distribution Rights This document and trademark(s) contained herein are protected by law. This representation of RAND intellectual property is provided for noncommercial use only. Unauthorized posting of this publication online is prohibited. Permission is given to duplicate this document for personal use only, as long as it is unaltered and complete. Permission is required from RAND to reproduce, or reuse in another form, any of its research documents for commercial use. For information on reprint and linking permissions, please visit www.rand.org/pubs/permissions.html. www.rand.org Should Canada “Start Low and Go Slow” When It Comes to Cannabis Potency? Testimony of Beau Kilmer1 The RAND Corporation2 Before the Standing Committee on Social Affairs, Science, and Technology Senate of Canada May 7, 2018 hairperson Eggleton, Deputy Chairperson Petitclerc, Deputy Chairperson Seidman, and other distinguished members of the Standing Committee on Social Affairs, Science, and C Technology, thank you very much for the opportunity to testify before you today.
    [Show full text]
  • Gold Rush to Green Rush: Cannabis Cultivation on Yurok Tribal Lands
    From Gold Rush to Green Rush: Cannabis Cultivation on Yurok Tribal Lands Kaitlin Reed Ph.D. Candidate, Native American Studies, University of California, Davis Charles Eastman Fellow of Native American Studies, Dartmouth College “The New World is in fact a very old world.” Anderson, M. Kat. Tending the Wild: Native American Knowledge and the Management of California's Natural Resources. Berkeley: University of California Press, 2005. 2019 North American Cannabis Summit 2 California Indians “Pre Contact”: over 1 million 1769: ~500,000 Native people living in California 1900: Less than 20,000 2019 North American Cannabis Summit 3 3 Waves of California Genocide Spanish Missionization (1769-1820) Mexican-American War (1821-1845) Gold Rush/Formation of California (1846- 1873) 2019 North American Cannabis Summit 4 2019 North American Cannabis Summit 5 Environmental Impacts of Gold Mining . Food depletion . Impacts to water quantity/quality . Mercury contamination . Destruction of other natural resources, e.g. timber 2019 North American Cannabis Summit 6 Yurok Tribal Lands 2019 North American Cannabis Summit 7 2019 North American Cannabis Summit 8 Gold Rush Green Rush 1. Land Dispossession 2. Indian Removal 3. Cultural Sovereignty 4. Ecological Colonialism 5. Impacts to Water 6. Impacts to Wildlife 7. Prioritization of Profit 8. Generational Impacts 2019 North American Cannabis Summit 9 Rush Mentality The Rush mentality is what founded Humboldt County… people act like that was so long ago and we have just definitely moved on and we’re just this very green friendly place, we’re liberals, we’re leftist. This is how people think of Humboldt County but what founded us is this Gold Rush and we have been rushing ever since, and so after the Gold Rush ‘well, gold didn’t make us enough money, let’s rush any kind of minerals that we can get’ and then after that you have ‘well that didn’t make us enough, let’s rush timber’ and then after – you know what I mean? … And I think we’ve been rushing since 1849.
    [Show full text]
  • Clearing the Smoke on Cannabis Edible Cannabis Products, Cannabis Extracts and Cannabis Topicals
    7 Clearing the Smoke on Cannabis Edible Cannabis Products, Cannabis Extracts and Cannabis Topicals Robert Gabrys, Ph.D., Research and Policy Analyst, CCSA Key Points • Edible cannabis products, cannabis extracts and cannabis topicals have unique health and safety risks that are not inherent to dried cannabis. • High-potency cannabis extracts increase the risk of over-intoxication more This is the seventh in a series of than dried cannabis. Although limited, the available evidence indicates that reports that reviews the effects of frequent use of these products is associated with problematic cannabis use, cannabis use on various aspects of cannabis use disorder and mental health disorders. human functioning and development. • Edible cannabis products can increase the risk of over-consumption and Other reports in this series address subsequent over-intoxication and impairment. Because when unpackaged they look like ordinary food and beverage products, edible cannabis products the link between regular cannabis use also increase the risk of unintentional ingestion, especially by children. and mental health, regular cannabis • Research on cannabis topicals, including the use of topical and transdermal use and cognitive functioning, maternal cannabidiol products, is limited. There is, however, growing interest among cannabis use during pregnancy, dermatologists and consumers in these cannabis products. cannabis use and driving, respiratory • The health impacts associated with long-term use of edible cannabis and cardiovascular effects of smoking products, cannabis extracts and cannabis topicals are not known. cannabis, and the medical use of • Public education efforts will play an important role in mitigating the harms cannabis and cannabinoids. This series associated with new cannabis products.
    [Show full text]
  • Personal Use Cannabis Rules Special Adopted New Rules: N.J.A.C
    NEW JERSEY CANNABIS REGULATORY COMMISSION Personal Use Cannabis Rules Special Adopted New Rules: N.J.A.C. 17:30 Adopted: August 19, 2021 by New Jersey Cannabis Regulatory Commission, Dianna Houenou, Chair. Filed: August 19, 2021 Authority: N.J.S.A. 24:6I-31 et seq. Effective Date: August 19, 2021 Expiration Date: August 19, 2022 This rule may be viewed or downloaded from the Commission’s website at nj.gov/cannabis. These rules are adopted pursuant to N.J.S.A. 24:6I-34(d)1a of the New Jersey Cannabis Regulatory, Enforcement Assistance, and Marketplace Modernization Act, N.J.S.A. 24:6I- 31 et seq., and became effective upon acceptance for filing by the Office of Administrative Law. The specially adopted new rules shall be effective for a period not to exceed one year from the date of filing of the new rules, that is, until August 19, 2022. The Commission has provided this special adoption to the Attorney General, State Treasurer, Commissioner of Health, and Commissioner of Banking and Insurance for a consultation period, after which the Commission anticipates filing a proposal to readopt these rules with amendments reflecting the results of that consultation. In accordance with N.J.S.A. 24:6I-34(d)1b the rules, as readopted, will become effective upon acceptance for filing by the Office of Administrative Law if filed on or before the expiration date of the rules published herein. The adopted amendments will be effective upon publication in the New Jersey Register. Federal Standards Analysis The Cannabis Regulatory, Enforcement Assistance, and Marketplace Modernization Act obliges the Cannabis Regulatory Commission to promulgate rules necessary or proper to enable it to carry out the Commission’s duties, functions, and powers with respect to overseeing the development, regulation, and enforcement of activities associated with the personal use of cannabis pursuant to P.L.2021, c.16.
    [Show full text]